Laura Estevez-Garcia
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy.
Journal: Scientific reports
Published: November 06, 2024
Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.
Journal: International journal of molecular sciences
Published: February 22, 2024
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2022
The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer.
Journal: Frontiers in immunology
Published: September 28, 2021
Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment.
Journal: Cancers
Published: May 26, 2021
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2020
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.
Journal: Cancer treatment reviews
Published: June 26, 2019
Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies.
Journal: Future oncology (London, England)
Published: April 04, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026